Maze Therapeutics Financials - Benzinga

Maze Therapeutics Inc

MAZENASDAQ

Trade with Public

Trade with Public

$28.31

0.501.80%

Last update: Aug 6, 1:42 PM

Overview News Earnings Forecast Events Price TargetsFinancialsSentiment Ownership Compare Options Stock Report

Maze Therapeutics Financials

Maze Therapeutics (MAZE) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Maze Therapeutics Q1 EPS $(0.45) Beats $(0.56) Estimate, Sales $20.000M Beat $9.286M Estimate

Maze Therapeutics (NASDAQ:MAZE) reported quarterly losses of $(0.45) per share which beat the analyst consensus estimate of $(0.56) by 19.64 percent. This is a 60.87 percent increase over losses of $(1.15) per share from

Benzinga Newsdesk

Earnings Scheduled For March 25, 2026

Benzinga Insights

PRO
Maze Therapeutics Q4 EPS $(0.65) Beats $(0.71) Estimate

Maze Therapeutics (NASDAQ:MAZE) reported quarterly losses of $(0.65) per share which beat the analyst consensus estimate of $(0.71) by 8.45 percent.

Benzinga Newsdesk

PRO
Maze Therapeutics Q3 EPS $(0.66) Beats $(0.71) Estimate

Benzinga Newsdesk

PRO
Maze Therapeutics Q2 EPS $(0.77) Misses $(0.76) Estimate

Benzinga Newsdesk

PRO
Maze Therapeutics Q1 EPS $(1.15) Up From $(13.91) YoY

Maze Therapeutics (NASDAQ:MAZE) reported quarterly losses of $(1.15) per share. This is a 91.73 percent increase over losses of $(13.91) per share from the same period last year.

Benzinga Newsdesk